Core business, India growth to offset Revlimid pain
As India’s pharmaceutical sector kicks off its earnings season for the quarter ended December on Friday, analysts expect muted margins. A key reason for this is the loss of patent exclusivity for the blood cancer drug Revlimid in the US. While the Revlimid loss is expected to hit overall US sales, steady domestic growth and…